Functional analysis of RET with Hirschsprung mutations affecting its kinase domain

Gastroenterology

Volumn 121, Issue 1, 2001, Pages 24-33

  Iwashita, T ^a   Kurokawa, K ^a   Qiao, S ^a   Murakami, H ^a   Asai, N ^a   Kawai, K ^a   Hashimoto, M ^a   Watanabe, T ^a   Ichihara, M ^a   Takahashi, M ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA TRANSFECTION; ENZYME ACTIVITY; GENE MUTATION; HIRSCHSPRUNG DISEASE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE RET; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SIPPLE SYNDROME;

EID: 0034950648     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2001.25515     Document Type: Article

References (64)

1. Activation of a novel human transforming gene, ret, by DNA rearrangement
2. Expression of the c-ret proto-oncogene during mouse embryogenesis
3. Spatial and temporal expression of the ret proto-oncogene product in embryonic, infant and adult rat tissues
4. Functional receptor for GDNF encoded by the c-ret proto-oncogene
5. GDNF-induced activation of the Ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF
6. Characterization of a multicomponent receptor for GDNF
7. GDNF signalling through the Ret receptor tyrosine kinase
8. Neurturin responsiveness requires a GPI-linked receptor and the Ret receptor tyrosine kinase
9. TrnR2, a novel receptor that mediates neurturin and GDNF signaling through Ret
10. A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor
11. Persephin, a novel neurotrophic factor related to GDNF and Neurturin
12. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRal-pha3-RET receptor complex
13. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
14. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma
15. Single missense mutation in the tyrosine-kinase catalytic domain of the RET proto-oncogene is associated with multiple endocrine neoplasia type 2B
16. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN2A and FMTC
17. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A
18. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET Mutation Consortium analysis
19. Mechanism of activation of ret proto-oncogene by multiple endocrine neoplasia 2A mutation
20. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B
21. RET activation by germline MEN2A and MEN2B mutations
22. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation
23. Distinct biological properties of two RET isoforms activated by MEN2A and MEN2B mutations
24. The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype
25. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype
26. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma
27. Hirschsprung's disease: Genetic mutations in mice and men
28. Mutations of the RET proto-oncogene in Hirschsprung's disease
29. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease
30. A missense mutation of the endothelin-B receptor gene in multigenic Hirschsprung's disease
31. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor RET
32. De-novo mutations of the RET proto-oncogene in Hirschsprung's disease
33. Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung disease
34. Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease
35. Endothelin receptor-mediated signaling in Hirschsprung disease
36. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumors, and Hirschsprung disease
37. Frequency of RET mutations in long-and short-segment Hirschsprung disease
38. Mechanism of Ret dysfunction by Hirschsprung mutations affecting its extracellular domain
39. Molecular heterogeneity of RET loss of function in Hirschsprung's disease
40. Co-segregation of MEN2 and Hirschsprung's disease: The same mutation of RET with both gain and loss-of-function?
41. Loss of function effect of RET mutations causing Hirschsprung disease
42. A mutation in the RET proto-oncogene in Hirschsprung's disease affects the tyrosine kinase activity associated with multiple endocrine neoplasia type 2A and 2B
43. Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease
44. Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effector to a multifunctional docking site
45. The role of amino acids surrounding tyrosine 1062 in Ret in specific binding of the Shc phosphotyrosine binding
46. Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKs): Evidence for a divergence of the ERKs and JNKs pathways induced by Ret
47. A mutation at tyrosine 1062 in MEN2A-RET and MEN2B-RET impairs their transforming activity and association with Shc adaptor proteins
48. RET alternate splicing influences the interaction of activated RET with the SH2 and PTB domains of Shc, and the SH2 domain of Grb2
49. Identification of Shc docking site on Ret tyrosine kinase
50. Shc and Enigma are both required for mitogenic signaling by Ret/ptc2
51. Ret receptor tyrosine kinase activates extracellular signal-regulated kinase 2 in SK-N-MC cells
52. Glial cell line-derived neurotrophic factor signals through the RET receptor and activates mitogen activated protein kinase
53. Cell scattering of SK-N-MC neuroepithelioma cells in response to Ret and FGF receptor tyrosine kinase activation is correlated with sustained ERK2 activation
54. Ret-dependent and -independent mechanism of glial cell line-derived neurotrophic factor signaling in neuronal cells
55. Glial cell line-derived neurotrophic factor induces Ret-mediated lamellipodia formation
56. Rho-dependent and -independent tyrosine phosphorylation of focal adhesion kinase, paxillin and p130Cas mediated by Ret kinase
57. Transforming activity of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway
58. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase C gamma
59. Signaling through Ras is essential for Ret oncogene-induced cell differentiation in PC12 cells
60. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor
61. Neuronal differentiation signals are controlled by nerve growth factor receptor/Trk binding site for SHC and PLC gamma
62. Hb Costa Rica or alphabeta(EF1) His→Arg: The first example of a somatic cell mutation in a globin gene
63. Androgen resistance associated with a mutation of the androgen receptor at amino acid 772 (Arg→Cys) results from a combination of decreased messenger ribonucleic acid levels and impairment of receptor function
64. Altered RET gene mRNA expression in Hirschsprung's disease